Sae-Bom Kwon, Gopichand Chinta, Sreenath Kundimi, Sangback Kim, Young-Dae Cho, Seul-Ki Kim, Jae-Yeong Ju, Krishanu Sengupta
{"title":"罗望子和莪术提取物混合物可缓解碘乙酸钠（MIA）诱发的大鼠骨关节炎疼痛和关节炎症。","authors":"Sae-Bom Kwon, Gopichand Chinta, Sreenath Kundimi, Sangback Kim, Young-Dae Cho, Seul-Ki Kim, Jae-Yeong Ju, Krishanu Sengupta","doi":"10.1080/27697061.2023.2209880","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>NXT15906F6 (TamaFlex<sup>TM</sup>) is a proprietary herbal composition containing <i>Tamarindus indica</i> seeds and <i>Curcuma longa</i> rhizome extracts. NXT15906F6 supplementation has been shown clinically effective in reducing knee joint pain and improving musculoskeletal functions in healthy and knee osteoarthritis (OA) subjects. The objective of the present study was to assess the possible molecular basis of the anti-OA efficacy of NXT15906F6 in a monosodium iodoacetate (MIA)-induced model of OA in rats.</p><p><strong>Methods: </strong>Healthy male Sprague Dawley rats (age: 8-9 wk body weight, B.W.: 225-308 g (<i>n</i> = 12) were randomly assigned to one of the six groups, (a) vehicle control, (b) MIA control, (c) Celecoxib (10 mg/kg B.W.), (d) TF-30 (30 mg/kg B.W.), (e) TF-60 (60 mg/kg B.W.), and (f) TF-100 (100 mg/kg B.W.). OA was induced by an intra-articular injection of 3 mg MIA into the right hind knee joint. The animals received either Celecoxib or TF through oral gavage over 28 days. The vehicle control animals received intra-articular sterile normal saline.</p><p><strong>Results: </strong>Post-treatment, NXT15906F6 groups showed significant (<i>p</i> < 0.05) dose-dependent pain relief as evidenced by improved body weight-bearing capacity on the right hind limb. NXT15906F6 treatment also significantly reduced the serum tumor necrosis factor-α (TNF-α, <i>p</i> < 0.05) and nitrite (<i>p</i> < 0.05) levels in a dose-dependent manner. mRNA expression analyses revealed the up-regulation of collagen type-II (COL2A1) and down-regulation of matrix metalloproteinases (MMP-3, MMP-9 and MMP-13) in the cartilage tissues of NXT15906F6-supplemented rats. Cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) protein expressions were down-regulated. Decreased immunolocalization of NF-κβ (p65) was observed in the joint tissues of NXT15906F6-supplemented rats. Furthermore, microscopic observations revealed that NXT15906F6 preserved MIA-induced rats' joint architecture and integrity.</p><p><strong>Conclusion: </strong>NXT15906F6 reduces MIA-induced joint pain, inflammation, and cartilage degradation in rats.</p>","PeriodicalId":29768,"journal":{"name":"Journal of the American Nutrition Association","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A Blend of <i>Tamarindus Indica</i> and <i>Curcuma Longa</i> Extracts Alleviates Monosodium Iodoacetate (MIA)-Induced Osteoarthritic Pain and Joint Inflammation in Rats.\",\"authors\":\"Sae-Bom Kwon, Gopichand Chinta, Sreenath Kundimi, Sangback Kim, Young-Dae Cho, Seul-Ki Kim, Jae-Yeong Ju, Krishanu Sengupta\",\"doi\":\"10.1080/27697061.2023.2209880\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>NXT15906F6 (TamaFlex<sup>TM</sup>) is a proprietary herbal composition containing <i>Tamarindus indica</i> seeds and <i>Curcuma longa</i> rhizome extracts. NXT15906F6 supplementation has been shown clinically effective in reducing knee joint pain and improving musculoskeletal functions in healthy and knee osteoarthritis (OA) subjects. The objective of the present study was to assess the possible molecular basis of the anti-OA efficacy of NXT15906F6 in a monosodium iodoacetate (MIA)-induced model of OA in rats.</p><p><strong>Methods: </strong>Healthy male Sprague Dawley rats (age: 8-9 wk body weight, B.W.: 225-308 g (<i>n</i> = 12) were randomly assigned to one of the six groups, (a) vehicle control, (b) MIA control, (c) Celecoxib (10 mg/kg B.W.), (d) TF-30 (30 mg/kg B.W.), (e) TF-60 (60 mg/kg B.W.), and (f) TF-100 (100 mg/kg B.W.). OA was induced by an intra-articular injection of 3 mg MIA into the right hind knee joint. The animals received either Celecoxib or TF through oral gavage over 28 days. The vehicle control animals received intra-articular sterile normal saline.</p><p><strong>Results: </strong>Post-treatment, NXT15906F6 groups showed significant (<i>p</i> < 0.05) dose-dependent pain relief as evidenced by improved body weight-bearing capacity on the right hind limb. NXT15906F6 treatment also significantly reduced the serum tumor necrosis factor-α (TNF-α, <i>p</i> < 0.05) and nitrite (<i>p</i> < 0.05) levels in a dose-dependent manner. mRNA expression analyses revealed the up-regulation of collagen type-II (COL2A1) and down-regulation of matrix metalloproteinases (MMP-3, MMP-9 and MMP-13) in the cartilage tissues of NXT15906F6-supplemented rats. Cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) protein expressions were down-regulated. Decreased immunolocalization of NF-κβ (p65) was observed in the joint tissues of NXT15906F6-supplemented rats. Furthermore, microscopic observations revealed that NXT15906F6 preserved MIA-induced rats' joint architecture and integrity.</p><p><strong>Conclusion: </strong>NXT15906F6 reduces MIA-induced joint pain, inflammation, and cartilage degradation in rats.</p>\",\"PeriodicalId\":29768,\"journal\":{\"name\":\"Journal of the American Nutrition Association\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Nutrition Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/27697061.2023.2209880\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/5/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Nutrition Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/27697061.2023.2209880","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 1
摘要
背景和目的：NXT15906F6（TamaFlexTM）是一种专有草药成分，含有罗望子种子和莪术根茎提取物。临床显示，补充 NXT15906F6 能有效减轻健康和膝关节骨关节炎（OA）受试者的膝关节疼痛并改善肌肉骨骼功能。本研究的目的是评估 NXT15906F6 在碘乙酸钠（MIA）诱导的大鼠 OA 模型中抗 OA 疗效的可能分子基础。W.: 225-308 g (n = 12)）随机分配到六个组中的一组，即（a）药物对照组，（b）MIA 对照组，（c）塞来昔布（10 mg/kg B.W.）组，（d）TF-30（30 mg/kg B.W.）组，（e）TF-60（60 mg/kg B.W.）组，以及（f）TF-100（100 mg/kg B.W.）组。右后膝关节内注射3毫克MIA诱发OA。动物通过口服塞来昔布或 TF 治疗 28 天。载体对照组动物接受无菌生理盐水关节内注射：结果：治疗后，NXT15906F6 组显示出显著的（p p p p 结论：NXT15906F6 和 TF 组动物的膝关节损伤程度明显低于对照组：NXT15906F6 可减轻 MIA 引起的大鼠关节疼痛、炎症和软骨退化。
A Blend of Tamarindus Indica and Curcuma Longa Extracts Alleviates Monosodium Iodoacetate (MIA)-Induced Osteoarthritic Pain and Joint Inflammation in Rats.
Background and objective: NXT15906F6 (TamaFlexTM) is a proprietary herbal composition containing Tamarindus indica seeds and Curcuma longa rhizome extracts. NXT15906F6 supplementation has been shown clinically effective in reducing knee joint pain and improving musculoskeletal functions in healthy and knee osteoarthritis (OA) subjects. The objective of the present study was to assess the possible molecular basis of the anti-OA efficacy of NXT15906F6 in a monosodium iodoacetate (MIA)-induced model of OA in rats.
Methods: Healthy male Sprague Dawley rats (age: 8-9 wk body weight, B.W.: 225-308 g (n = 12) were randomly assigned to one of the six groups, (a) vehicle control, (b) MIA control, (c) Celecoxib (10 mg/kg B.W.), (d) TF-30 (30 mg/kg B.W.), (e) TF-60 (60 mg/kg B.W.), and (f) TF-100 (100 mg/kg B.W.). OA was induced by an intra-articular injection of 3 mg MIA into the right hind knee joint. The animals received either Celecoxib or TF through oral gavage over 28 days. The vehicle control animals received intra-articular sterile normal saline.
Results: Post-treatment, NXT15906F6 groups showed significant (p < 0.05) dose-dependent pain relief as evidenced by improved body weight-bearing capacity on the right hind limb. NXT15906F6 treatment also significantly reduced the serum tumor necrosis factor-α (TNF-α, p < 0.05) and nitrite (p < 0.05) levels in a dose-dependent manner. mRNA expression analyses revealed the up-regulation of collagen type-II (COL2A1) and down-regulation of matrix metalloproteinases (MMP-3, MMP-9 and MMP-13) in the cartilage tissues of NXT15906F6-supplemented rats. Cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) protein expressions were down-regulated. Decreased immunolocalization of NF-κβ (p65) was observed in the joint tissues of NXT15906F6-supplemented rats. Furthermore, microscopic observations revealed that NXT15906F6 preserved MIA-induced rats' joint architecture and integrity.
Conclusion: NXT15906F6 reduces MIA-induced joint pain, inflammation, and cartilage degradation in rats.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
